Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Oncolytic immunotherapy

How Turnstone is combining an oncolytic virus with cancer vaccines

Steve Edelson, Senior Editor
February 22, 2016 8:00 AM UTC

Turnstone Biologics Inc. is combining an oncolytic virus with cancer vaccines, which it anticipates will result in products with efficacy advantages over each individual modality.

Turnstone's origins trace to the Ottawa Hospital Research Institute lab of scientific co-founder John Bell, where two of his postdocs, David Stojdl and Brian Lichty, were studying oncolytic viruses from different angles. The institute is affiliated with the University of Ottawa. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article